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We examined the effects of exisulind (sulindac sul-
fone) and a potent derivative CP248 on the Barrett’s
esophagus (BE)-related adenocarcinoma cell lines
Seg-1 and Bic-1, and on HCE7 esophageal squa-
mous carcinoma cells. Marked growth inhibition and
apoptosis occurred in all cell lines with IC50 values of
100–300M for exisulind and 100 nM for CP248.
Bic-1 and HCE7 cells were more sensitive to the
growth inhibitory properties of exisulind. Treatment
of all cell lines with CP248 for 24 h increased the
proportion of cells in mitosis. Exisulind had no effect
on cell-cycle progression. Treatment with either
compound induced rapid activation of the c-Jun
NH2-terminal kinase 1 (JNK1), suggesting that JNK1
activation plays a role in the induction of apoptosis by
these compounds. Only Seg-1 cells expressed a
detectable basal level of cyclooxygenase-2 (cox-2),
providing further evidence that cox-2 is not the crit-
ical target for the growth inhibitory and apoptotic
effects of these compounds. Cellular levels of
reduced glutathione (GSH) increased approximately
five-fold in all cell lines after 24 h of treatment with
either compound. These studies provide support for
the use of exisulind in BE chemoprevention trials, and
of exisulind or CP248 in the therapy of patients with
esophageal carcinoma.
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INTRODUCTION
Barrett’s esophagus (BE) is a premalignant
lesion that develops usually as a conse-
quence of chronic gastroesophageal reflux
disease (1). The risk of esophageal adenocar-
cinoma in this population is comparable to
the risk of colon cancer in patients with
ulcerative colitis. During the past 15 years,
the incidence of BE-associated adenocar-
cinoma (BAA) has greatly increased in both
North America and Europe (1,2). For this
reason, there is considerable interest in pro-
moting surveillance of patients with BE to
detect early-stage cancers, in developing
molecular markers to predict cancer risk,
and in developing novel approaches to the
prevention and treatment of BAA. At the pre-
sent time, there are no proven approaches to
chemoprevention of this disease.
Preclinical and clinical evidence support a
role for nonsteroidal anti-inflammatory
drugs (NSAIDs) in the prevention of colorec-
tal and other gastrointestinal malignancies
(3–5). Exisulind (sulindac sulfone) is a meta-
bolite of the NSAID sulindac, and CP248 is a
highly potent synthetic analog of exisulind
(6). Previous investigations have demon-
strated significant anticancer activities of
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these compounds in a variety of human can-
cer cell lines, including colon, breast, and
prostate cancer cell lines (5–10). However,
there are no published studies of their effects
in esophageal cancer cells. Exisulind and
CP248 belong to a unique group of com-
pounds that induce apoptosis through a
recently described novel signaling pathway.
In SW480 colon cancer cells, these drugs
increase cellular levels of cyclic GMP (cGMP)
through the inhibition of cGMP phosphodies-
terases (2,5), leading to the activation of pro-
tein kinase G (PKG). The subsequent
induction of apoptosis appears to be due to
PKG-mediated degradation of -catenin and
activation of JNK1, but additional targets
may also play a role (11–13). CP248 can
also induce a marked cell-cycle arrest in
mitosis, by interfering with microtubule poly-
merization (14). In contrast to sulindac and
other NSAIDs, neither exisulind nor CP248
inhibits cyclooxygenase activity. Further-
more, exisulind and CP248 appear to act
independently of p53 (5,6) and are not inhib-
ited by bcl-2 overexpression (6). Exisulind
also inhibits chemical carcinogenesis and
tumor growth in various animal models
(5,8,15). Exisulind is currently being studied
as a chemoprevention agent for patients with
familial adenomatous polyposis (FAP) who
are at risk for the development of colon can-
cer (16). It is also being studied for use in
combination with cytotoxic chemotherapy
agents for the management of patients with
various types of advanced malignancies (17).
In view of the above findings, exisulind is a
potential chemoprevention agent for patients
with BE. As described above, this population
represents a unique group of patients who
are at risk for cancer and who undergo rou-
tine surveillance during which esophageal
tissue can be obtained to monitor the effects
of various types of treatment. Therefore, we
initiated the present studies to provide sup-
port for the use of this drug in the prevention
and treatment of BAA. For this purpose, we
utilized two cell lines originally derived from
BAA, Seg-1 and Bic-1, and for comparison,
we also included the human esophageal
squamous carcinoma cell line HCE7.
Because of its unique properties, we also
examined in parallel with exisulind, the
effects of CP248 on cell proliferation, apopto-
sis, and specific biomarkers.
MATERIALS AND METHODS
Compounds and Antibodies
Exisulind and CP248 were obtained from
Cell Pathways, Inc (Horsham, PA). The com-
pounds were supplied in powder form, dis-
solved in dimethylsulfoxide (DMSO; Sigma,
St. Louis, MO), and added directly to cell-
culture medium at a final concentration of
0.1% DMSO. The following primary anti-
bodies were obtained: cyclin D1 (Upstate Bio-
technology, Lake Placid, NY), p27Kip1 (Santa
Cruz, Santa Cruz, CA), cox-2 (Oxford
Biomed, Oxford, MI), PKG (Calbiochem, San
Diego, CA), and actin (Sigma). Propidium
iodide (PI) was obtained from Sigma.
Cell Culture
The BAA cell lines Seg-1 and Bic-1, were
developed from patients with BAA by
Dr. David G. Beer (University of Michigan, Ann
Arbor, MI) and grown in Dulbecco’s modified
Eagle’s medium (Life Technologies, Grand
Island, NY) supplemented with 10% fetal
bovine serum (FBS) (Life Technologies).
HCE7 human esophageal squamous carcin-
oma cells (18,19) were grown in RPMI-
1640 medium (Life Technologies) with 10%
FBS. All of the cell lines were maintained at
37 C in a 5%CO2 atmosphere.
Cell-Proliferation Assays
Cell proliferation was measured using the
MTT Cell Proliferation Kit I (Boehringer-
Mannheim,Indianapolis,IN),whichcolorimetri-
cally measures a purple formazan compound
produced by viable cells. Cells were plated in
flat-bottomed, 96-well microtiter plates
(4103 cells/6.4mm-diameter well). After
12–24h, cells were treated with DMSO
(0.1%) or increasing doses of exisulind or
CP248. After 48h of treatment, cells were
treated with 10l of the MTT reagent for 4h
at 37 C, and then with 100l of solubiliza-
tion solution at 37 C overnight. The quantity
of formazan product was measured using a
spectrophotometric microtiter plate reader
(Dynatech Laboratories, Alexandria, VA) at
570nm wavelength. Results were expressed
as percent growth, with 100% representing
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control cells treated with DMSO alone. All
experiments were performed in triplicate.
Apoptosis Assays
The percent of cells actively undergoing
apoptosis was determined using annexin
V-phycoerythrin (PE)-based immunofluores-
cence, as previously described (20). Briefly,
cells were plated in 10–cm culture dishes at
concentrations to yield 60–70% confluence
within 24h. Cells were then treated with
DMSO (0.1%), exisulind (300M) or CP248
(200nM). After 48h of treatment, both
adherent and floating cells were harvested
and then double-labeled with annexin
V-PE and 7-aminoactinomycin (7-AAD)
(PharMingen, San Diego, CA), as described by
the manufacturer. Cells were analyzed using a
FACScan instrument equipped with FACSta-
tion running Cell Quest software (Becton
Dickinson, San Jose, CA). All experiments
were performed in duplicate.
Cell-Cycle Distribution Analysis
PI staining was used to analyze DNA content.
Cells were plated in 10-cm culture dishes at
concentrations to yield 60–70% confluence
within 24h. Cells were then treated with
DMSO (0.1%), exisulind (300M), or CP248
(200nM). After a 24-h treatment, both adher-
ent and floating cells were harvested and
labeled with PI, as previously described (6).
Briefly, cells were resuspended in phosphate-
buffered saline (PBS), fixed with 70% etha-
nol, labeled with PI (0.05mg/ml), incubated
at room temperature in the dark for 30min,
and filtered through 41-m spectra/mesh
nylon filters (Spectrum, Rancho Dominguez,
CA). DNA content was then analyzed using a
FACScan instrument equipped with FACSta-
tion running Cell Quest software. All experi-
ments were performed in triplicate.
Assay to Identify Cells in Mitosis
An assay, which measures the binding of an
antibody, anti-MPM2 (mitotic phosphopro-
tein 2), to a mitosis-specific phosphorylated
epitope MPM2 was used to determine the
proportion of cells undergoing mitosis, as
described previously (21). Cells were plated
in 10-cm culture dishes at concentrations to
yield 60–70% confluence within 24h. Cells
were treated with either DMSO (0.1%) or
CP248 (200nM). After 24h of treatment,
cells were harvested and treated with 70%
ethanol. Cells were resuspended in PBS con-
taining 2% FBS, incubated with the primary
anti-MPM2 antibody (Upstate Biotechnology)
for 30min at room temperature in the dark,
then with fluorescein isothiocyanate (FITC)-
labeled antimouse antibody (Rockland,
Gilbertsville, PA) for 30min in the dark at room
temperature, and finally with PI (0.01mg/
ml). Prior to analysis, samples were filtered
through 41-m spectra/mesh filters (Spec-
trum). DNA content and fluorescein activity
were then analyzed using a FACScan instru-
ment equipped with FACStation running Cell
Quest software (Becton Dickinson). All
experiments were performed in triplicate.
JNK1 Kinase Assays
The methods for in vitro JNK1 kinase assays
have been previously described in detail (12).
Briefly, Seg-1 cells were plated in 10-cm
culture dishes at concentrations to yield
60–70% confluence within 24h. Cells were
treated with 0.1% DMSO, 300M exisulind,
or 200nM CP248 and harvested after 2 and
24h. After cell lysis, JNK1 was immunopre-
cipitated with an anti-JNK1 antibody (Santa
Cruz) for 2h and assayed for in vitro kinase
activity with GST-c-Jun (1–79) (New England
Biolab, Beverly, MA) as the substrate in a
kinase reaction buffer for 20min. The
reaction mixture was then subjected to 10%
SDS-PAGE. The extent of protein phosphor-
ylation was determined using autoradiogra-
phy. Experiments were performed in
duplicate.
Protein Extraction and Western Blotting
The methods for protein extraction and West-
ern blot analysis have been described pre-
viously (22). Briefly, cells were treated with
0.1% DMSO (negative control), exisulind
(300M), or CP248 (200nM). Experiments
involving cox-2 analysis also included
cells treated with 12-O-tetradecanoylphorbol-
13-acetate (TPA) (100ng/ml) for 5h (positive
control). After 24–48h of treatment, cell lysates
were prepared, and 60–100g of protein was
separated by SDS-PAGE (10%). After transfer
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to nitrocellulose membranes (Millipore,
Bedford, MA), blots were blocked with 5% milk
protein, incubated for 1h with the indicated
primary antibody, and then reincubated for
1h with the corresponding horseradish
peroxidase-conjugated secondary antibody.
Protein–antibody complexes were detected by
the enhanced chemiluminescence system
(Amersham, Piscataway, NJ). Immunoblotting
for actin was performed to verify equivalent
amounts of loaded protein.
GSH Induction
Cells were plated in 10-cm culture dishes at
concentrations to yield 60–70% confluence
within 24h. Cells were treated with 0.1%
DMSO, exisulind (300M), or CP248
(200nM). Cells were harvested after 3h and
24h of treatment, and then lysed in 200mM
methane sulfonic acid. Precipitates were dis-
solved in 0.1N NaOH. Concentrations of GSH
were measured using a Perkin-Elmer high
performance liquid chromatography (HPLC)
equipped with a 4-channel coulometric
array detector (ESA, Inc., Chelmsford, MA).
The final concentrations of GSH were
reported as nmol/mg protein. (For additional
details, please refer to (23)).
Statistical Analyses
Data are expressed as meanSD. Compari-
sons between DMSO-treated control cells
and exisulind- or CP248-treated cells were
made using the Student’s t test. Differences
between groups of P50.01 or P50.001
were considered statistically significant.
RESULTS
Growth Inhibition by Exisulind and
CP248
To demonstrate the antitumor activities of
exisulind and CP248 in human esophageal
carcinoma cells, we investigated their effects
on cell growth in cell lines of different histo-
logic subtypes. Two BAA cell lines Seg-1 and
Bic-1, were compared with the HCE7 eso-
phageal squamous carcinoma cell line. Expo-
nentially dividing cells were treated with
increasing concentrations of either exisulind
(50–500 M) or CP248 (25–400nM). Both
exisulind and CP248 caused statistically
significant growth inhibition, in a dose-
dependent fashion, in all three cell lines after
48h of treatment, with IC50 values of
150–300M and 50–100nM, respectively
(Figure 1). Bic-1 and HCE7 cells were about
twice as sensitive to growth inhibition by
exisulind than Seg-1 cells. CP248 was about
1000 times more potent than exisulind, and all
threecell linesappeared tobeequally sensitive to
this compound.
Apoptosis Induction by Exisulind and
CP248
Because exisulind and CP248 inhibited the
growth of the three esophageal cancer cell
lines, we determined whether these com-
pounds also induced apoptosis. For these
and most of our subsequent studies, we
used doses of exisulind and CP248 that were
at least one to two times the IC50 value for
each cell type (300M exisulind and 200nM
CP248). When the three esophageal cancer
cells were treated for 48h, there was a marked
induction of apoptosis. Results with HCE7
cells are shown in Figure 2. The percentage
of apoptotic cells increased from 5.9% in con-
trol DMSO-treated cells to 15.1 and 24.2%
after treatment with exisulind and CP248,
respectively. Similarly, treatment with exisu-
lind or CP248 for 48h induced apoptosis in
Bic-1 cells (from a control value of 8.2 to
18.6% and 21.0%, respectively) and in Seg-1
cells (from a control value of 0.4 to 6.3% and
53.9%, respectively) (data not shown). There-
fore, our studies demonstrate that Seg-1 cells
are less sensitive than Bic-1 and HCE7 cells
to both growth inhibition (Figure 1A) and
apoptosis induction by exisulind. Exisulind
and CP248 also induced apoptosis in each of
the cell lines after 24h of treatment, although
to an extent less than that observed after the
48–h treatment (data not shown). Our results
are consistent with previous studies, which
demonstrated that exisulind and CP248
induce apoptosis in colon and prostate cancer
cell lines (6,11,12).
Effects on Cell-Cycle Progression
We examined the effects of exisulind
and CP248 on cell-cycle progression in
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exponentially dividing cultures of these three
cell lines. Subconfluent cultures of cells
were treated with DMSO alone, exisulind
(300M), or CP248 (200nM). Since we were
interested in evaluating the distribution of
actively dividing cells prior to the induction
of extensive apoptosis, we harvested the cells
at 24h, rather than at 48h. The cells were
then labeled with PI and analyzed by DNA
flow cytometry. Representative DNA histo-
grams for the Bic-1 cells are shown in Figure 3.
Similar results were seen with Seg-1 and
HCE7 cells (Table 1). In all three cell lines,
CP248 induced a striking accumulation
Figure 1. Growth inhibition of esophageal carcinoma cells after treatment with exisulind or CP248 for 48 h. Exponentially dividing cells were
treated with increasing concentrations of exisulind (A) or CP248 (B). Cell viability was determined using the MTT assay. The percent of growth
was calculated with 100% representing control cells treated with 0.1% dimethylsulfoxide (DMSO) alone. The results are the meansSD from
triplicate experiments (*, P50.01).
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of cells in the G2/M phase of the cell
cycle. In contrast, exisulind did not induce
significant changes in cell-cycle distribution
(Figure 3 and Table 1).
Because of CP248’s striking ability to
arrest esophageal cancer cells in the G2/M
phase, it was of interest to determine
whether the CP248-treated cells were speci-
fically arrested in mitosis, and to confirm
that treated cells were not simply tetraploid
cells in the G1 phase. Cells that were treated
with either 0.1% DMSO or 200nM CP248
were harvested after 24h, dual-labeled with
PI and a FITC-conjugated monoclonal anti-
body directed against the MPM2 protein, and
then analyzed by flow cytometry. MPM2
labeling specifically identifies cells in mitosis
(21). Seg-1 cells treated with DMSO alone
displayed minimal (2%) MPM2 labeling
(Figure 4). However, in the CP248-treated
cells, about 50% of the G2/M arrested cells
were MPM2-positive. Therefore, CP248
causes esophageal cancer cells to arrest in
mitosis. Similar results were observed in
CP248-treated HCE7 and Bic-1 cells (data
not shown).
JNK1 Activation
Our previous studies have shown that when
human colon cancer cells are treated with
exisulind or CP248, there is rapid activation
of the signaling molecule JNK1, and that this
activation may play a critical role in the
induction of apoptosis by these and related
compounds (12). Therefore, we investigated
whether rapid activation of JNK1 also occurs
when esophageal cancer cells are treated
with exisulind or CP248. Seg-1 cells were
Figure 2. Apoptosis induction. HCE7 cells were treated with 0.1% dimethylsulfoxide (DMSO), 300M exisulind, or 200 nM CP248 for 48 h.
Cells were double-stained with annexin V-phycoerythrin and 7-aminoactinomycin and analyzed for apoptosis by DNA flow cytometry. The
data indicate the percentage of cells, which are annexin V-positive (apoptotic). Similar results were obtained in duplicate experiments.
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treated with 0.1% DMSO, 300M exisulind
or 200nM CP248 and assayed for JNK1
activation after 2 and 24h of treatment
(Figure 5). Endogenous JNK1 was immuno-
precipitated with an anti-JNK1 antibody,
and in vitro kinase assays were performed
with GST-c-Jun as the substrate. Treatment
of Seg-1 cells with both exisulind and CP248
led to rapid (within 2h) activation of JNK1.
As previously seen with colon cancer cells
(12), CP248 activated JNK1 more strongly
than did exisulind. Moreover, JNK1 activa-
tion was sustained for at least 24h with
CP248.
Cox-2 Induction in Seg-1 Cells
Because of the interest in increased cox-2
expression in a variety of human cancers
(24–27), and the fact that a number of
NSAIDs inhibit cox-2 enzymatic activity, we
examined this marker in our esophageal
cancer cell lines. Seg-1 cells were treated
with 0.1% DMSO (negative control), TPA
Figure 3. Cell-cycle analysis of Bic-1 cells after treatment with 0.1% dimethylsulfoxide (DMSO), 300M exisulind, or 200 nM CP248. After
24 h of treatment, cells were labeled with propidium iodide (PI) and analyzed by DNA flow cytometry. The data indicate the percentage of cells
in each phase of the cell cycle. Similar results were obtained in triplicate experiments.
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(100ng/ml, positive control for induction of
cox-2 (28)), exisulind (300M), or CP248
(200nM). After 5h of treatment with TPA or
48h of treatment with either exisulind or
CP248, cell extracts were analyzed for
levels of cox-2 by Western blotting (Figure 6).
Seg-1 cells expressed a basal level of cox-2,
and as expected TPA markedly induced
the level of its expression. Surprisingly, both
exisulind and CP248 also induced the
expression of cox-2. However, Bic-1 and
HCE7 cells did not express detectable basal
levels of cox-2, nor was cox-2 induced by
TPA, exisulind, or CP248 in these cell lines
(data not shown).
Induction of Reduced Glutathione
Glutathione-S-transferase (GST) and glu-
tathione play important roles in cancer pre-
disposition and carcinogen detoxification
(29). Therefore, it was of interest to measure
the effects of exisulind and CP248 on cellular
levels of GSH using an HPLC-based assay.
Seg-1 cells were treated with 0.1% DMSO,
exisulind (300M), or CP248 (200nM). Cells
were harvested after 3 and 24h of treatment,
and total cellular concentrations of GSH were
measured using a Perkin-Elmer HPLC. Exi-
sulind and CP248 markedly induced cellular
levels of GSH after 3 and 24h of treatment,
with a two- to 2.5-fold increase at 3h and a
six-to eight-fold increase at 24h (Figure 7).
Both compounds also caused similar
increases in GSH in Bic-1 and HCE7 cells
(data not shown).
DISCUSSION
The purpose of this study was to provide
support for the development of exisulind
and related drugs as chemopreventive and
anticancer agents in patients with BE and
Table 1. Cell cycle distribution of esophageal cancer cell lines
after treatment for 24 h with dimethyl sulfoxide DMSO (0.1%),
exisulind (300 M), or CP248 (200 nM).
Distribution (% cells)*
Cell Line G1 S G2/M
Bic-1 DMSO 54.3 3.6 25.7 2.8 19.9 1.6
Exisulind 56.8 3.0 21.8 2.4 21.3 1.1
CP248 1.9  0.4y 2.5 0.3y 95.7 0.6y
Seg-1 DMSO 59.3 2.9 18.0 3.5 22.7 1.5
Exisulind 60.2 0.8 15.8 1.9 24.0 1.1
CP248 7.0  1.7y 9.1  2.2 83.9 0.8y
HCE7 DMSO 48.2 1.8 21.3 0.9 30.4 2.4
Exisulind 57.2 3.6 19.0 4.5 23.7 1.0
CP248 4.4  0.1y 9.6 0.7y 86.0 0.8y
*DNA content was analyzed using PI staining and DNA flow
cytometry (Figure 3). The data indicate the percent of cells in
each phase of the cell cycle. The values are the meanSD of
triplicate assays.
y P50.001.
Figure 4. Analysis for percent of Seg-1 cells in mitosis (mitotic
phosphoprotein 2 (MPM2)-positive) after treatment with 0.1%
dimethylsulfoxide (DMSO) or 200 nM CP248. After 24 h of
treatment, cells were labeled with propidium iodide (PI) and the
MPM2 antibody as described in Materials and Methods, and
analyzed by DNA flow cytometry. Similar results were obtained in
triplicate experiments.
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esophageal cancer, respectively. Both exisu-
lind and a potent derivative CP248 were pre-
viously shown to induce growth inhibition
and apoptosis in several human cancer cell
lines, including breast, colon, and prostate
cancer cell lines (6,9,12)(and unpublished
studies). However, these compounds had
not been previously studied in esophageal
cancer cell lines. Our results indicate that
exisulind and CP248 display strong antipro-
liferative activity in both the BAA cell lines
Seg-1 and Bic-1, and the esophageal squa-
mous carcinoma cell line HCE7. Both com-
pounds caused a dose-dependent inhibition
of growth in all three cell lines with IC50
values of about 150–300M and 50–100nM
for exisulind andCP248, respectively (Figure 1).
These values are similar to those found
with other human cancer cell lines
(6,11,12), although it appears that the Seg-1
cell line may be less sensitive than the Bic-1
and HCE7 cell lines to the growth inhibitory
effects of exisulind (Figure 1). As previously
seen with other types of cancer cell lines
(6,12), exisulind and CP248 also induced
apoptosis in both the adenocarcinoma and
squamous cell carcinoma esophageal cancer
cell lines (Figure 2 and data not shown),
although the Seg-1 cells were less sensitive
to apoptosis induction by exisulind than
the Bic-1 and HCE7 cells. However, all
three cell lines were equally sensitive to
growth inhibition and apoptosis induction
by CP248.
Cell-cycle analysis indicated that when
these three esophageal cancer cell lines
were treated with CP248 for 24h, there was
a marked arrest of the cell cycle in G2/M,
and a major fraction of the cells were specific-
ally arrested in mitosis (Figures 3 and 4,
Table 1, and data not shown). The ability of
CP248 to induce G2/M arrest has been pre-
viously seen in both prostate (6) and glioblas-
toma cell lines (14), and apparently reflects
the ability of this compound to impair micro-
tubule polymerization (14). On the other
hand, exisulind did not have a significant
effect on cell-cycle progression in our three
esophageal cancer cell lines (Figure 3 and
Table 1). In prostate cancer cells, exisulind
induces partial arrest in the G1/S phase (6),
Figure 5. Activation of c-jun NH2-terminal kinase 1 (JNK1) in Seg-1
esophageal cancer cells. Seg-1 cells were treated with 0.1%
dimethylsulfoxide (DMSO), 300M exisulind, or 200 nM CP248 for
2 or 24 h. In vitro JNK1 activity was measured as described in
Materials and Methods.
Figure 6. Cyclooxygenase-2 (cox-2) protein expression in Seg-1 esophageal cancer cells after treatment with 0.1% dimethylsulfoxide
(DMSO), 100 ng/ml 12-O-tetradeconoylphorbol-13-acetate (TPA), 300M exisulind, or 200 nM CP248. After 48 h of treatment, cell lysates
were evaluated for cox-2 expression by Western blotting.
Figure 7. Glutathione induction in Seg-1 cells after treatment with
exisulind or CP248. Seg-1 cells were treated with 0.1%
dimethylsulfoxide (DMSO) for 24 h and 300 M exisulind or
200 nM CP248 for 3 or 24 h. Cellular levels of reduced glutathione
were determined as described in Materials and Methods.
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but it does not induce significant arrest in
any specific phase of the cell cycle in MCF7
breast cancer cells, glioma cells, or colon
cancer cells, and it does not impair microtu-
bule polymerization (9,14)(and unpublished
studies). The extremely potent effects of
CP248 on growth inhibition and apoptosis
in esophageal cancer cell lines seen in the
present study may be due, at least in part,
to its ability to arrest these cells in mitosis.
Soh et al., recently obtained evidence that
induction of apoptosis in SW480 cells by exi-
sulind, CP248, and related compounds was
due, at least in part to PKG-mediated activa-
tion of JNK1 (12). Mechanistic studies in
NIH-3T3 cells also established a novel path-
way by which the activation of PKG leads to
activation of JNK1 (13). These findings are
consistent with previous evidence that
JNK1, and other stress-activated protein
kinases, play important roles in mediating
cellular stress responses, including apopto-
sis, induced by other agents (30,31). In the
present study, we found that rapid activation
of JNK1 also occurred in Seg-1 cells after
treatment with exisulind or CP248, and
with CP248, this activation was sustained
for at least 24h (Figure 5). Therefore, JNK1
activation probably also plays an important
role in the induction of apoptosis by exisu-
lind and CP248 in esophageal cancer cells.
GST and glutathione play important roles
in carcinogen detoxification. GSH, an endo-
genous tripeptide thiol, functions as an anti-
oxidant and protects cells from damage by
free radicals, xenobiotic compounds, and
other cellular toxins (29). The biologically
active reduced form is readily measured
usingHPLC (23).WhenSeg-1cellswere treated
with exisulind or CP248, within 3h there
was a moderate increase, and at 24h a
marked increase (about six-to eight-fold) in
cellular levels of GSH (Figure 7). Similar
results were seen with Bic-1 and HCE7 cells
(data not shown). The mechanism respon-
sible for this increase is unclear, but could
reflect either an increase in de novo synthesis
by gamma glutamyl synthetase or a decrease
in cellular utilization of GSH. GSH induction
has previously been seen with various
NSAIDs (32) and garlic derivatives (33) and
could contribute to the anticancer effects of
these compounds. Compton et al. (34) found
that levels of GST- mRNA and protein were
lower in tissue samples of BE metaplasia
than innormal esophagealmucosa.Decreased
levels of this phase 2 detoxification enzyme
may contribute to the increased susceptibility
to carcinogenesis in this metaplastic tissue.
Thus, our findings of GSH induction with
exisulind and CP248 may provide an addi-
tional rationale for using these compounds as
chemopreventive agents.
There is considerable current interest in
the use of selective cox-2 inhibitors as chemo-
prevention agents (35–37). Several types
of evidence suggest that cox-2 plays an
important role in the development of various
gastrointestinal malignancies, including
those of the esophagus, stomach, colorec-
tum, liver, and pancreas (24,25). An
increase in the cox-2 protein has been
detected in BE and BAA (27), as well as in
esophageal high-grade dysplasia and eso-
phageal squamous cell carcinoma (26).
Selective cox-2 inhibitors have been shown
to reduce polyp development in FAP patients
(37). Therefore, in the present study, we
investigated the levels of cox-2 at baseline
and after treatment with exisulind and
CP248 in the three esophageal cancer cell
lines. We found that the Seg-1 cells
expressed a detectable basal level of cox-2
(Figure 6), but we could not detect cox-2
expression in either Bic-1 or HCE7 cells
(data not shown). Although cox-2 mRNA
was detected in 70–80% of BE and BAA tis-
sue specimens, the frequency of cox-2 pro-
tein expression in these samples was not
reported (38). Therefore, it is not clear what
proportion of BE lesions or BAA are likely to
respond to selective cox-2 inhibitors. Sur-
prisingly, we found that cox-2 was actually
induced by both exisulind and CP248 in
Seg-1 cells within 5h of treatment, and was
further induced after 24–48h of treatment
(Figure 6, and data not shown). The mechan-
ism of this induction is not known. It was
recently reported that microtubule-interfering
agents, including colchicine and paclitaxel,
induce cox-2 mRNA and protein in
human mammary epithelial cells (39). This
could explain the induction of cox-2 by
CP248, since CP248 also disrupts microtu-
bule assembly (14). On the other hand, exi-
sulind also induced cox-2 expression in Seg-1
cells, and yet it does not cause mitotic
arrest (Figure 3 and Table 1) or disrupt the
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cellular cytoskeleton (14). Cox-2 induction
has also been reported during HIV-1 gp120-
induced apoptosis (40), generalized inflam-
mation (41), and increased mechanical loading
stress (42,43). Therefore, the induction
of cox-2 by CP248 and exisulind in Seg-1
cells may occur through nonspecific
mechanisms. It is of interest that despite
differences in basal levels of cox-2 expres-
sion, all three cell lines were sensitive to
the antiproliferative effects of exisulind and
CP248. Indeed, the cox-2-negative Bic-1
and HCE7 cells were more sensitive to the
growth inhibitory and apoptosis-inducing
effects of exisulind than the cox-2-positive
Seg-1 cells. These findings provide further
evidence that cox-2 is not the critical target
for the antitumor effects of exisulind and
CP248. They are also consistent with pre-
vious studies indicating that exisulind and
CP248 do not inhibit the in vitro activities of
cox-1 or cox-2 (5,6).
CONCLUSION
In summary, exisulind and CP248 inhibit
growth and induce apoptosis in both
BE-related adenocarcinoma and esophageal
squamous carcinoma cells by a cox-2-
independent mechanism. Both compounds
are very potent activators of JNK1. However,
only CP248 can induce mitotic arrest and
inhibit microtubule polymerization. This
dual effect may explain the higher potency
of CP248 when compared with that of exi-
sulind. These compounds may therefore be
useful in preventing the development of eso-
phageal adenocarcinoma in patients with BE
and, when used alone or in combination with
other agents, in the treatment of patients
with adenocarcinoma or squamous carcin-
oma of the esophagus. In clinical studies,
assays for apoptosis, JNK1 activation, and
GSH levels in tissue biopsy specimens
may provide useful surrogate intermediate
endpoints.
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